Welcome to our dedicated page for Moleculin Biotec news (Ticker: MBRX), a resource for investors and traders seeking the latest updates and insights on Moleculin Biotec stock.
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical-stage pharmaceutical company advancing novel therapies for resistant cancers and viral diseases. This news hub provides investors and researchers with essential updates on clinical developments, regulatory milestones, and scientific breakthroughs.
Access timely announcements about Annamycin's progress through late-stage trials for acute myeloid leukemia (AML), WP1066's immune-modulating potential, and strategic partnerships advancing oncology research. Our curated collection includes press releases on FDA designations, trial protocol updates, and peer-reviewed study publications.
Key coverage areas include non-cardiotoxic anthracycline developments, orphan drug status achievements, and preclinical data on metabolic pathway inhibitors. Bookmark this page for verified updates on Moleculin's innovative approaches to overcoming multidrug resistance in cancer treatment.
Moleculin Biotech, Inc. (Nasdaq: MBRX) will report its Q1 2024 financial results on May 10, 2024. The company focuses on drug candidates for hard-to-treat tumors and viruses. A conference call and webcast to discuss the results will be held on May 13, 2024, at 8:30 AM ET.
Moleculin Biotech, Inc. reports positive interim data for Annamycin in treating acute myeloid leukemia (AML). The CRc rate reached 62% in 1st and 2nd line AML subjects, with a 45% CRc in the full MB-106 trial. The presentation of data supports advancing to a Phase 2 trial (MB-108) for potential New Drug Approval. A virtual AML Clinical Day was held on May 7, 2024. Key data shows promising results and progression towards registration for Annamycin in AML.
Moleculin Biotech, Inc. (Nasdaq: MBRX) will host a virtual AML Clinical Day featuring Dr. Martin Tallman, discussing the unmet medical needs in AML treatment, Annamycin, and the Company's AML clinical development program. The event will highlight the ongoing progress of Annamycin towards a pivotal AML study in 2024 for potential accelerated approval.
Moleculin Biotech, Inc. announced the formation of its Annamycin Scientific Advisory Board, appointing Dr. Martin Tallman as the inaugural clinician member. Dr. Tallman, an internationally renowned clinician, brings extensive experience in leukemia-targeting therapies. The company aims to advance the development of Annamycin, a promising treatment for AML and STS lung mets.
FAQ
What is the current stock price of Moleculin Biotec (MBRX)?
What is the market cap of Moleculin Biotec (MBRX)?
